To determine if the same gene expression changes were occurring in clinical breast tumors with MLL3 mutations, we utilized RNA‐seq data from TCGA ER+ luminal breast cancer patients; this analysis revealed 688 upregulated and 693 downregulated genes based on MLL3 mutation status, q < 0.05. This evidence concerns the gene KMT2C and breast carcinoma.